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Abstract
Commensal organisms are frequent causes of pneumonia. However, the detection of these organisms in the airway does
not mean that they are the causative pathogens; they may exist merely as colonizers. In up to 50% cases of pneumonia, the
causative pathogens remain unidentified, thereby hampering targeting therapies. In speculating on the role of a commensal
organism in pneumonia, we devised the battlefield hypothesis. In the ‘‘pneumonia battlefield,’’ the organism-to-human cell
number ratio may be an index for the pathogenic role of the organism. Using real-time PCR reactions for sputum samples,
we tested whether the hypothesis predicts the results of bacteriological clinical tests for 4 representative commensal
organisms: Streptococcus pneumoniae, Haemophilus influenzae, Pseudomonas spp., and Moraxella catarrhalis. The cutoff
value for the organism-to-human cell number ratio, above which the pathogenic role of the organism was suspected, was
set up for each organism using 224 sputum samples. The validity of the cutoff value was then tested in a prospective study
that included 153 samples; the samples were classified into 3 groups, and each group contained 93%, 7%, and 0% of the
samples from pneumonia, in which the pathogenic role of Streptococcus pneumoniae was suggested by the clinical tests.
The results for Haemophilus influenzae, Pseudomonas spp., and Moraxella catarrhalis were 100%, 0%, and 0%, respectively.
The battlefield hypothesis enabled legitimate interpretation of the PCR results and predicted pneumonia in which the
pathogenic role of the organism was suggested by the clinical test. The PCR reactions based on the battlefield hypothesis
may help to promote targeted therapies for pneumonia. The prospective observatory study described in the current report
had been registered to the University Hospital Medical Information Network (UMIN) registry before its initiation, where the
UMIN is a registry approved by the International Committee of Medical Journal Editors (ICMJE). The UMIN registry number
was UMIN000001118: A prospective study for the investigation of the validity of cutoff values established for the HIRA-TAN
system (April 9, 2008).
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Introduction
Pneumonia is a common disease and is one of the most frequent
causes of deaths worldwide. Only 2-dozen species of pathogens are
responsible for the most cases of pneumonia. Nevertheless, the
causative pathogen cannot be identified by clinical tests such as
cultures or serological tests in up to 50% of the cases [1].
Multidisciplinary maneuvers including history taking, physical
examination, imaging studies, and epidemiological information
complement the clinical test; they help clinicians to list pathogens
likely to be the cause and to select antibiotics that can be used to treat
them. However, more information than this is often required,
especially when a patient is in a serious condition and the pathogens
that should be intensivelytargeted need to beidentified without delay.
The polymerase chain reaction (PCR)-based test for purulent
sputum is an excellent complementary maneuver. First, if a
pathogen is not detected by PCR, the pathogen is less likely to be
the causative pathogen, because PCR reaction is sensitive and can
detect even a small number of pathogen cells. Second, PCR can
detect non-commensal organisms (i.e., organisms that does not
colonize in the airway as exemplified by Mycoplasma pneumoniae and
Mycobacterium tuberculosis); if they are detected, they are most likely
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24474to be the causative pathogen. Third, PCR is quick, and the result
can be delivered to the clinicians in an early phase of the
treatment. A major problem associated with a PCR-based test is its
inability to discriminate a commensal organism causing pneumo-
nia from the same organism colonizing the airway [2]. These
organisms include Streptococcus pneumoniae (S. pneumoniae), Haemophilus
influenzae (H. influenzae), Pseudomonas spp., and Moraxella catarrhalis
(M. catarrhalis)( Table 1). Because they are frequent causes of
pneumonia, PCR-based tests that can discriminate these 2 states of
commensal organisms are desired.
A definite identification of the causative pathogen of pneumonia
is difficult. Instead, a commensal organism is often considered
likely to be a causative pathogen when it is (1) detected in the
peripheral blood, (2) observed by Gram staining followed by
confirmation by sputum culture, (3) phagocytosed by leukocytes in
the sputum, or (4) the antigen is detected in the urine antigen test
[1,3,4,5,6,7,8,9,10]. These criteria have provided legitimate results
and thus have been used in clinical practice. Therefore, we
considered these criteria as a surrogate endpoint for the
identification of the causative pathogen and aimed to establish a
PCR-based test of the sputum that provides consistent results. To
attain this aim, we devised the ‘‘battlefield hypothesis,’’ in which
the ratio of pathogen cells to human inflammatory cells in the
sputum is an index for the dominance of the pathogen in the
pneumonia ‘‘battlefield.’’ The hypothesis reflects the principle
that, in every battle, the relative number of combatants is a major
determinant of the current state of battle. In the current study, we
demonstrate that the interpretation of the PCR results using the
battlefield hypothesis paralleled the results of bacteriological tests.
Our results warrant clinical studies that investigate the utility of the
PCR-based test in the treatment of pneumonia.
Methods
Criteria
Pneumonia: A diagnosis of pneumonia was made when patients
presented with both (1) acutely developed symptoms such as fever,
cough, sputum, or chest pain and (2) newly developed pulmonary
infiltrates in an imaging study [1,3,4].
Likely causative pathogen: By reviewing a variety of guidelines
[1,3,4,5,6,7,8,9], we identified 4 criteria that suggested causative
pathogens in the bacteriological tests widely used in clinical
medicine. A commensal organism that fulfilled at least 1 of the
following 4 criteria was considered likely to be a causative
pathogen when: (1) an organism was detected in the peripheral
blood; (2) a morphologically compatible organism was observed
through Gram staining later confirmed by sputum culture; (3) for
S. pneumoniae, H. influenzae, and M. catarrhalis only: a morpholog-
ically compatible organism coexisted with neutrophils (.100 per
visual field at a magnification of 1006) that phagocytosed the
organism; or (4) for S. pneumoniae only: the urine antigen test was
positive.
Table 1. List of pneumonia-causing pathogens.
Proportion in community-acquired
pneumonia
[11,12,13,14,15,16,17,18] &
Proportion in hospital-acquired
pneumonia
[19,20,21,22,23] &
Commensal organisms 44.94% 94.29%
Streptococcus pneumoniae 24.50% 3.40%
Haemophilus influenzae 6.04% 5.32%
Moraxella catarrhalis 0.62% 2.75%
Pseudomonas spp. 0.99% 25.25%
Enterobacteriaceae 3.37% 19.88%
Klebsiella pneumoniae 3.74%
others
$ 16.14%
Stenotrophomonas maltophilia 2.50%
Staphylococcus aureus 2.40% 18.39%
MSSA 4.57%
MRSA 13.82%
Others
# 7.02% 16.80%
Non-commensal organisms 34.56%
Mycoplasma pneumoniae 11.18%
Chlamydophila pneumoniae 8.78%
Chlamydophila psittaci 0.36%
Legionella spp. 2.78%
Mycobacterium Tuberculosis 2.64%
Pneumocystis jiroveci 1.12%
others* 7.70%
Unknown or normal flora 20.50% 5.71%
& values indicated are the averages from the references cited.
$ includes Escherichia coli, Enterobacter species, Proteus species, and Serratia species.
# includes anaerobes, Staphylococcus species (other than S. aureus), Streptococcus species (other than S. pneumoniae), Acinetobacter species, and Aspergillus species.
*includes viruses and Coxiella burnetii.
doi:10.1371/journal.pone.0024474.t001
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Target Gene Oligo Sequence Probe conc. Size Reference
(Genbank
Accession No.)
Human SFTPC
(U02948)
F# 59-GCAGTGCCTACGTCTAAGCTG-39 0.3 mM1 3 0 b p
B5 9-TAGATGTAGTAGAGCGGCACCTC-39
D FAM-CGAGATGCAGGCTCAGCACCCTC-TAMRA
Commensal organisms
Streptococcus pneumoniae Pneumolysin
(M17717)
F5 9-CTAAGGCTTGGGACAGAAATGGGC-39 0.3 mM1 7 2 b p
B5 9-CCGCTTACGCACTAGTGGCAAATC-39
D TET-AGGGAATGTTCGCAATCTCTCTGTCA-BHQ-1
Haemophilus influenzae 16S rRNA
(Z22806)
F5 9-TTGACATCCTAAGAAGAGCTCAGAGA-39 0.3 mM2 6 7 b p
B5 9-CTTCCCTCTGTATACGCCATTGTAGC-39
D TET-ATGGCTGTCGTCAGCTCGTGTT-BHQ-1
Moraxella catarrhalis copB
(U69982)
F5 9-CGTGCGTGTTGACCGTTTTGACTTTA-39 0.3 mM2 9 8 b p
B5 9-CACGCTGCCAAAAATAACTGCCAAAG-39
D TET-CAGCGGTAACCTAATCTATGCCACTC-BHQ-1
Pseudomonas spp. 16S rRNA
(AY486350)
F5 9-GACGGGTGAGTAATGCCTAGGA-39 0.3 mM 618 bp [24]
B5 9-CCACTGGTGTTCCTTCCTATATCT-39
D TET-AGTGGGGGATCTTCGGACCTCA-BHQ-1
Non-commensal organisms
Mycoplasma pneumoniae 16S rRNA
(NC_000912)
F5 9-AGTAATACTTTAGAGGCGAACGGGTGA-39 0.3 mM 227 bp [25]
B5 9-TCTACTTCTCAGCATAGCTACACGTCA-39
D FAM-ACCAACTAGCTGATATGGCGCA-TAMRA
Chlamydophila pneumoniae 53KD-antigen
(E12535)
F5 9-GCAACCACGGTAGCAACACAAATTA-39 0.3 mM3 6 4 b p
B5 9-AATTGAGCGACGTTTTGTTGCATCT-39
D FAM-AGCGGCTGTCAAATCTGGAATAAAAG-TAMRA
Chlamydophila psittaci ompA (X56980) F 59-GTATGTTCATGCTTAAGGCTGTTTTCAC-39 0.1 mM2 9 1 b p
B5 9-TCCCACATAGTGCCATCGATTAATAAAC-39
D TET-CCAGAAGAGCAAATTAGAATAGCGAGCA-BHQ-1
Legionella pneumophila Mip (S72442) F 59-TAACCGAACAGCAAATGAAAGACG-39 0.1 mM 264 bp [25]
B5 9-AAAACGGTACCATCAATCAGACGA-39
D TET-TGATGGCAAAGCGTACTGCTGAA-BHQ-1
Legionella spp. 16S rRNA
(FR799709)
F5 9-AGGCTAATCTTAAAGCGCCAGGCC-39 0.1 mM 198 bp [26]
B5 9-GCATGCTTAACACATGCAAGTCGAAC-39
D FAM-CATATTCCTACGCGTTACTCACCCGT-TAMRA
Mycobacterium tuberculosis MPB64
(NC_000962)
F5 9-ATCCGCTGCCAGTCGTCTTCC-39 0.1 mM 238 bp [27]
B5 9-CTCGCGAGTCTAGGCCAGCAT-39
D TET-CCGGACAACAGGTATCGATAGCGCC-BHQ-1
Mycobacterium intracellulare ITS 16-23S rRNA
(AM709724)
F5 9-AGCACCACGAAAAGCACTCCAATT-39 0.1 mM2 4 3 b p
B5 9-CGAACGCATCAGCCCTAAGGACTA-39
D FAM-CCTGAGACAACACTCGGTCGATCC-TAMRA
Mycobacterium avium 16S rRNA
(M29572)
F5 9-CAAGTCGAACGGAAAGGCCTCT-39 0.3 mM2 5 7 b p
B5 9-GCCGTATCTCAGTCCCAGTGTG-39
D FAM-TACCGGATAGGACCTCAAGACGC-TAMRA
Battlefield Hypothesis for Pathogens in Pneumonia
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Sputum, induced sputum, or sputum obtained by intra-tracheal
aspiration (sputum hereafter) was isolated at the earliest conve-
nience, and at least within 48 h, after the diagnosis of newly
developed pneumonia had been established. This excluded the
experiment in which a temporal profile of DCtpathogen was observed
and thus the sputum was serially isolated for several days. Sputum
samples were mixed well by pipetting, and divided into 2; one was
submitted for a bacteriological test, and the other was submitted for
a PCR test. At the same time, a urine sample was submitted for a
urine antigen test. Sputum samples that were mostly serous
specimens, i.e., with a gross appearance of M1 according to Miller
and Jones’ classification [10], or with Cthuman $27 by PCR, were
considered inappropriate and were excluded from the study.
Patients
All patients were (a) 18 years of age or older, (b) diagnosed as
having pneumonia by the criteria described above. They also (c)
provided sputum that fulfilled the criteria described above, and (d)
provided written informed consent. Sample collection was
performed from May 2007 to March 2008 (the initial study for
determining the cutoff value) and from April 10, 2008 to October
9, 2008 (the prospective study) at the Saitama Medical University
Hospital and the participating institutes.
DNA preparation
The sputum was diluted with an equal volume of phosphate-
buffered saline and homogenized by vortexing. A portion of the
homogenate (200 mL) was taken and mixed with AL buffer
(200 mL; Qiagen, Tokyo, Japan) containing .12 mAU of
proteinase K, and the resultant mixture was incubated at 56uC
for 2 h. DNA was isolated into 100 mL of TE buffer with the
QIAamp DNA Blood Mini Kit (Qiagen).
Primers and probes
The specificity of the primer and the probe sequences to the 21
target genes was confirmed by a BLAST search of the GenBank
database. Each primer and probe set was then tested against a panel
that included DNA from 65 respiratory pathogens, 2 drug
resistance-related genes, and human genomic DNA (Table 2),
and was confirmed to exclusively amplify and detect its target DNA.
Real-time PCR reaction
The PCR reaction solution (25 mL) contained TAKARA
Premix Ex Taq (12.5 mL; Takara Bio Inc., Shiga, Japan), primers
(300 nM), fluorescence-labeled detection probes (100 nM or
300 nM; Table 2), and purified DNA (1 mL). The real-time
PCR reactions were performed using the SmartCycler II Real-
Time Thermal Cycler (Cepheid, Sunnyvale, CA, USA): for target
fragments longer than 500 bp, 95uC for 30 s followed by 40 cycles
of 95uC for 10 s, 61uC for 35 s, and 72uC for 25 s; for target
fragments shorter than 500 bp, 95uC for 30 s followed by 40 cycles
of 95uC for 8 s, 61uC for 25 s, and 72uC for 20 s.
Statistical analysis
The 95% confidence interval (CI) was calculated using the
formula for the binomial probabilities.
Ethical consideration
The research protocol for the current study was approved by
the institutional review boards of the Saitama Medical University
Hospital, Saitama International Medical Center, Kan-etsu
Target Gene Oligo Sequence Probe conc. Size Reference
(Genbank
Accession No.)
Mycobacterium kansasii dnaJ (AB292544) F 59-ACCCGTGTGATGAGTGCAAAGGC-39 0.1 mM2 3 1 b p
B5 9-GTAAAGCTGACCGGAACTGTGACG-39
D TET-AGGACGGACAGCGGATCAGACT-BHQ-1
Nocardia spp.* 16S rRNA (DQ659898) F 59-CCTTCGGGTTGTAAACCTCTTTCGAC-39 0.1 mM1 9 1 b p
B5 9-TTGGGGTTGAGCCCCAAGTTTTCA-39
D FAM-AAGAAGCACCGGCCAACTACGTGC-TAMRA
Pneumocystis jiroveci* large subunit ribosomal
RNA (AF461782)
F5 9-GTGTACGTTGCAAAGTACTCAGAAGA-39 0.3 mM 346 bp [28]
B5 9-GATGGCTGTTTCCAAGCCCA-39
B5 9-GATGGCTGTTTCCAAGCCCA-39
*These organisms may be found in a healthy airway on rare occasions. When detected in pneumonic patients, they are very likely to be the causative pathogen. We
therefore list them as non-commensal organisms.
# F: forward primer, B: backward primer, D: detection probe. Each primer set was tested against the DNA panel and was confirmed to provide specific amplification only
for its target sequence. The panel contains DNA from human, from 65 organisms, and from 2 organisms that harbor drug resistance-related genes; the organisms
include Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Pseudomonas aeruginosa, Klebsiella pneumoniae, Stenotrophomonas maltophilia,
Staphylococcus aureus, Mycoplasma pneumoniae, Chlamydophila pneumoniae, Chlamydophila psittaci, Legionella pneumophilia, Mycobacterium tuberculosis,
Mycobacterium intracellulare, Mycobacterium avium, Mycobacterium kansasii, Nocardia asteroids, Pneumocystis jiroveci, Acinetobacter baumannii, Anaerococcus
hydrogenalis, Aspergillus flavus, Aspergillus fumigates, Aspergillus niger, Bacteroides caccae, Bacteroides fragilis, Bacteroides thetaiotaomicron, Candida albicans, Candida
parapsilosis, Clostridium perfringens, Clostridium ramosum, Corynebacterium spp., Coxiella burnetii, Cryptococcus neoformans, Eikenella corrodens, Enterobacter aerogenes,
Enterobacter cloacae, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Haemophilus haemolyticus, Haemophilus parainfluenzae, Klebsiella oxytoca, Legionella
bozemanii, Legionella micdadei, Mycobacterium gordonae, Neisseria meningitides, Peptostreotococcus anaerobius, Porphyromonas asaccharolytica, Prevotella bivia,
Prevotella intermedia, Proteus mirabilis, Serratia marcescens, Staphylococcus auricularis, Staphylococcus epidermidis, Staphylococcus simulans, Streptococcus anginosus,
Streptococcus constellatus, Streptococcus intermedius, Streptococcus mitis, Streptococcus pyogenes, Streptococcus uberis, Trichosporon asahii, and Trichosporon mucoides;
drug resistance-related genes include IMP and mecA.
doi:10.1371/journal.pone.0024474.t002
Table 2. Cont.
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numa City Hospital and Saitama Social Insurance Hospital.
All patients were (a) 18 years of age or older, (b) diagnosed as
having pneumonia by the criteria described above. They also (c)
provided sputum that fulfilled the criteria described above, and (d)
provided written informed consent. Sample collection was
performed from May 2007 to March 2008 (the initial study for
determining the cutoff value) and from April 10, 2008 to October
9, 2008 (the prospective study) at the Saitama Medical University
Hospital and the participating institutes.
Results
Battlefield hypothesis
The battlefield hypothesis assumes that the ratio of the cells of a
commensal organism to human inflammatory cells is an index of
the pathogenic role of the organism (Figure 1A). In a quantitative
PCR-based system, with the use of primers and probes that
specifically quantitate the cell numbers of each pathogen or
human, the ratio of pathogen cells to human cells is log-
proportional to DCtpathogen=2(Ctpathogen2Cthuman)(Figure 1B).
As predicted by the battlefield hypothesis, the DCtpathogen cutoff is
a threshold value that can be used to discriminate a commensal
organism with a pathogenic role from the same organism simply
colonizing the airway (Figure 1C).
Determination of the DCtpathogen cutoff
We confirmed that the primers and probes used in the current
study were specific to 4 representative commensal organisms (S.
pneumoniae, H. influenzae, Pseudomonas spp., and M. catarrhalis) and to
human (Table 2), and were able to quantify their cell numbers in
sputum (Figure 2).
We then determined a PCR criterion that can select purulent
sputumsuitableforthetest,andexcludeM1samplesthat aremostly
saliva. We found that P1–P3 samples almost entirely had a Cthuman
of,27 (Figure3A).In the current study,sputumsamples that were
Figure 1. Battlefield hypothesis. (A) When pneumonia occurs, the numbers of both the causative pathogen and human inflammatory cells
increase at the inflammation site. Meanwhile, the colonizing pathogen lags behind. The ratio of pathogen to human cells may be a good indicator for
the differentiation of the causative pathogen from the colonizing pathogen. (B) The cell number ratio is measurable by quantitative PCR. The Ct
(threshold cycle) is the PCR cycle at which a statistically significant fluorescent signal is first observed. Ctpathogen is the Ct for the pathogen-specific
gene, Cthuman is the Ct for the human-specific gene, and both are log-proportional to the number of the cells (see Figure 2). Accordingly,
DCtpathogen= 2(Ctpathogen2Cthuman) is log-proportional to the ratio of pathogen to human cells. (C) Because DCtpathogen indicates the ratio of
pathogen to human cells, we may be able to determine the DCtpathogen cutoff, a DCtpathogen value above which a pathogenic role of the pathogen in
pneumonia is strongly suggested.
doi:10.1371/journal.pone.0024474.g001
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were considered suitable and investigated further.
We then screened pathogens using PCR (Figure 3B). Blue
circles represent the samples isolated from patients in whom the
organism was identified as a likely causative pathogen on the basis
of the said criteria (1) – (4). By setting the cutoff as the smallest
value of DCtpathogen, the samples were classified into 3 groups: (i)
Samples with DCtpathogen $ cutoff, in which case the organism was
considered to have a high chance of being a causative pathogen;
(ii) Samples with DCtpathogen , cutoff, in which case the organism
had a small chance of being a causative pathogen; (iii) samples in
which the organism was not detected, in which case the pathogen
was unlikely to be a causative pathogen.
The procedure for preparing DNA from the sputum included
homogenization of the sputum by digestion of its proteins, so that
the procedure was less affected by the viscosity of the sputum.
However, patients can expectorate sputum of different qualities at
different times. To study the variation between the samples, we
studied consecutive sample pairs, in which a pair contains 2
samples expectorated in a single day, and graphed 28 pairs in
which 1 of 4 commensal organisms was detected. For each case
examined, both samples in a pair were observed to be located on
the same side (either above or below) of the cutoff (Figure 3C).
This suggested that the variation between the samples did not
affect to a large extent to the classification of the sputum into 3
groups.
According to the battlefield hypothesis, the ratio of pathogen to
human cells is predicted to decrease with the clearance of bacterial
cells by inflammatory cells. We thus investigated the change in
DCtpathogen in the early days of treatment by studying 9
consecutive patients (Figure 3D). In all of them, the DCtpathogen
decreased during the treatment. This was consistent with the
speculation described above.
Prospective study
In order to confirm whether the suggested cutoff values
reproducibly identified pneumonia for cases in which the organism
had a good chance of being a likely causative pathogen, we
designed a prospective observatory study (see Table 3 for the
protocol). Here, we expanded the PCR reactions to cover 11 non-
commensal organisms and named the system HIRA-TAN
(HIRA=human cell-controlled identification of the respiratory
agent; ‘‘TAN’’ means sputum in Japanese; Table 2). A total of
153 samples were enrolled (Table 4). The primary endpoint was
the percentage of sputum that had a DCtpathogen value greater than
the cutoff value, when S. pneumoniae was the likely causative
pathogen (on the graph, it is the percentage of blue circles above
the red line). The proportion was 0.93 (37/40; 95% CI, 0.80–0.97)
(Figure 4A). The secondary endpoints were the percentages for
the other 3 commensal organisms. They were 1.0 (12/12; 95% CI,
0.74–0.998) for H. influenzae, 1.0 (12/12; 95% CI 0.74–0.998) for
Pseudomonas spp., and 1.0 (1/1; 95% CI undetermined) for M.
catarrhalis. These results indicated that the test was strong at
predicting the likelihood of the organism being a likely causative
pathogen; when DCtpathogen was greater than the cutoff value, S.
pneumoniae had a 66% chance (37 blue circles/56 blue + white
circles) of being a likely causative pathogen; when DCtpathogen was
smaller than the cutoff value, the chance was 7% (3/41); when S.
pneumoniae was not detected by PCR, the chance was 0% (0/56)
(Figure 4A). Comparative results were obtained for all of the
other organisms.
It is interesting to study the range of DCtpathogen values observed
when other organisms were a likely causative pathogen. In most of
the cases, DCtpathogen was less than the cutoff or the organism was
not detected (Figure 4B). This is consistent with our knowledge
that a single pathogen plays a dominant pathogenic role in most
cases of pneumonia.
Discussion
If PCR can provide legitimate information on a detected
commensal organism (i.e., pathogenic or colonizing), it will
become a more important test in clinical practice. The
interpretation of PCR results on the basis of the battlefield
hypothesis provided such information, which can be summarized
as follows: (i) an organism that presented a DCtpathogen value above
the cutoff had a good chance of being the likely causative
pathogen, (ii) an organism that presented a DCtpathogen below the
cutoff had a small chance of being the likely causative pathogen,
and (iii) an organism that was not detected was very unlikely to be
the likely causative pathogen.
In the current study, we studied 4 commensal organisms and
found that the battlefield hypothesis worked well for all of them.
However, it will be important to determine whether the hypothesis
is applicable to other commensal organisms, including Staphylococ-
cus aureus and Klebsiella pneumoniae, which are frequent causes of
pneumonia. We have expanded the list of target pathogens for the
HIRA-TAN to include these commensal organisms, and the
studies are in progress. Although the results are preliminary, the
battlefield hypothesis seems to be working for these 2 organisms as
well. Further studies are however necessary to confirm the results.
The immune reaction may be weak in the elderly and in
immunocompromised hosts; therefore, the DCtpathogen cutoff
suitable for these people may be different from that for other
individuals. In patients with weak immune reactions, the increase
in the number of inflammatory cells may be small. Hence, the
value of Cthuman may increase, thereby resulting in a larger
DCtpathogen according to the equation DCtpathogen=2(Ctpatho-
gen2Cthuman). Therefore, the use of the DCtpathogen cutoff
determined for patients with normal immunity is considered to
provide a margin of safety for those with compromised immunity,
which will be desirable in clinical practice.
The likely causative pathogen was not identified for half of the
samples with a DCtpathogen above the cutoff (white circles above the
red line, Figure 2A). Some of these samples are located in the
topmost part of the graph, and have a large ratio of pathogen-to-
human cell numbers. One possibility is that criteria (1) – (4) may
have a large false negative rate and failed to identify a portion of
the pathogens causing pneumonia [1]. Studies using sputum
isolated by bronchoscopy will be necessary to investigate this issue.
Figure 2. Relationship between cell number and Ct. Log-linear relationships between the copy number of pathogen-specific sequence and
Ctpathogen and between the copy number of the human-specific sequence and Cthuman. (A) S. pneumoniae, H. influenzae, Pseudomonas spp., or M.
catarrhalis was suspended in sputum. DNA was then purified from the suspension, and the target sequences specific to each organism were
amplified by PCR. A log-linear relationship indicates that the sputum does not contain molecules that inhibit isolation of DNA or exponential
amplification by PCR. Experiments were done in triplicate. A bar indicates standard deviation. (B) Human genomic DNA isolated from sputum was
serially diluted, and a DNA sequence in the human SFTPC gene (arbitrarily selected from human genes, of which sequence is specific to human by
BLAST search of GenBank database; Table 2) was amplified. A log-linear relationship indicates that the sputum does not contain molecules that
inhibit isolation of DNA or exponential amplification by PCR.
doi:10.1371/journal.pone.0024474.g002
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PLoS ONE | www.plosone.org 7 September 2011 | Volume 6 | Issue 9 | e24474Figure 3. Determination of the DCt cutoff. (A) Selection of purulent sputum. Sputum was classified by its gross appearance, with 50 samples
studied for each classification. Purulent sputum had a Cthuman ,27 (.7610
3 human cells/mL of sputum; Figure 2B). Samples with M2–P3
appearance as well as a Cthuman ,27 (enclosed by a dotted line) were studied further. Classification of the gross appearance of the sputum (M1, M2,
P1, P2, and P3) are according to Miller and Jones [10]. (B) Determination of the DCt cutoff. DCtpathogen was measured for 4 representative commensal
organisms (n=223). Samples from patients with pneumonia in which a likely causative pathogen was identified using criteria (1)–(4) (see Methods)
are shown as blue circles, and samples from patients with pneumonia in which none of criteria (1) – (4) was fulfilled were shown as white circles. The
DCtpathogen cutoff (a red line) was defined as the smallest DCtpathogen for the blue circles. Sputum in which the pathogen was not detected and thus
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PLoS ONE | www.plosone.org 8 September 2011 | Volume 6 | Issue 9 | e24474DCtpathogen was not assigned is shown at the bottom (labeled as ‘‘Not detected’’). (C) Reproducibility of DCtpathogen measurements. Duplicate samples
were isolated from a single patient in a single day (n=28), and each of the duplicate samples was independently measured for DCtpathogen. Both of
the measurements provided DCtpathogen located on the same side (above or below) of the cutoff. Red line: the cutoff for each organism. (D) Temporal
profile of DCtpathogen during antibiotic treatment. A single sample set contains multiple sputum samples isolated from a single patient during
antibiotic treatment. A total of 9 consecutive sample sets that included 7 of pneumonia with DCtpathogen for S. pneumoniae . cutoff and 2 of
pneumonia with DCtpathogen for H. influenzae . cutoff at day 1 were studied. DCtpathogen decreased to below the cutoff in the course of treatment.
doi:10.1371/journal.pone.0024474.g003
Table 3. Protocol for the prospective observatory study.
Study design A multi-institutional study. Sputum was collected from all outpatients and inpatients ($18 years of age) who developed
pneumonia.
Study period and sample size
# Between April 10, 2008 and April 9, 2009. The study will be terminated before April 9, 2009, when the total number of patients
reaches 300, or when the number of patients with pneumonia in which S. pneumoniae is the likely causative pathogen reaches
40.
Eligibility criteria All patients who provided sputum classified as M2, P1, P2 or P3 by the criteria of Miller and Jones [10]. Sputum is isolated at
the earliest convenience, at least within 48 h, after the diagnosis of newly developed pneumonia is established. Sputum is
divided into 2 samples; one is submitted for a bacteriological test including Gram staining and culture, and the other is
submitted for the HIRA-TAN test. The samples are also submitted for urine antigen test for S. pneumoniae.
Primary endpoint The proportion of samples in which S. pneumoniae was detected with a DCtpathogen $ cutoff to those in which S. pneumoniae
was shown to be a likely causative pathogen.
Secondary endpoints The proportion of the samples in which H. influenzae, M. catarrhalis,o rPseudomonas spp. was detected with a DCtpathogen $
cutoff to those in which each was shown to be a likely causative pathogen.
# The number was determined so that the primary endpoint is evaluated at a resolution of 0.1.
doi:10.1371/journal.pone.0024474.t003
Table 4. Patients’ characteristics.
Age (y) (Mean [min-max]) 65.9 (18–96)
Sex Male (%) 83 (54.2%)
Female (%) 70 (45.8%)
Sputum (Miller and Jones’ classification)
M2 (%) 31 (20.3%)
P1 (%) 38 (24.8%)
P2 (%) 22 (14.4%)
P3 (%) 62 (40.5%)
Cthuman (mean [min-max]) 24.58 (20.58–26.85)
Type of pneumonia
Community-acquired pneumonia (CAP) (%) 113 (73.9%)
Healthcare-associated pneumonia (HCAP) (%) 24 (15.7%)
Hospital-associated pneumonia (HAP) (%) 16 (10.5%)
Serum CRP (mg/dL) (Mean [min-max]) 11.0 (0.1–45.39)
Radiological feature Monolobar infiltrate 71 (46.4%)
Multilobar infiltrates 82 (53.6%)
Underlying disorder Neoplastic disease 5 (3.3%)
Congestive heart failure 18 (11.8%)
Cerebrovascular disease 25 (16.3%)
Renal disease 9 (5.9%)
Liver disease 4 (2.6%)
Chronic respiratory disease 49 (26.1%)
Lung cancer 9 (5.9%)
Collagen vascular disease 19 (12.4%)
Steroid usage 13 (8.5%)
Diabetes 15 (9.8%)
doi:10.1371/journal.pone.0024474.t004
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PLoS ONE | www.plosone.org 9 September 2011 | Volume 6 | Issue 9 | e24474Figure 4. A prospective study. (A) DCtpathogen for each commensal organism (n=153). Samples in which real-time PCR failed to detect the
organism are shown at the bottom (‘‘Not detected’’). The DCtpathogen cutoff demarcated well the samples obtained from the patients in whom the
likely causative pathogen was identified by criteria (1) – (4). (B) Interrelationship between the pathogens detected. Samples obtained from the
patients in whom the other 3 commensal organisms were identified as a likely causative pathogen or samples in which a non-commensal organism
was detected by real-time PCR are colored. Most of the colored circles are located below the cutoff line.
doi:10.1371/journal.pone.0024474.g004
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PLoS ONE | www.plosone.org 10 September 2011 | Volume 6 | Issue 9 | e24474An important question is whether the information provided by
the battlefield hypothesis and its implementation as HIRA-TAN
will be useful in clinical practice. We found that HIRA-TAN was
readily applicable to clinical practice; the consumables are 2 US
dollars/pathogen and the results have been delivered to clinicians
in 4 h at our institute. Considering that HIRA-TAN covers
pathogens frequently involved in pneumonia, and that the results
can be delivered early in the course of treatment, we anticipate
that patients with pneumonia will benefit from HIRA-TAN, thus
warranting clinical studies.
In conclusion, the battlefield hypothesis enabled legitimate
interpretation of PCR results and predicted pneumonia in which
the organism is a likely causative pathogen. By providing
information on the pathogens in pneumonia, HIRA-TAN will
help promoting targeted therapies for pneumonia.
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